{"id":36810,"date":"2026-09-23T14:33:50","date_gmt":"2026-09-23T09:03:50","guid":{"rendered":"https:\/\/khabreindia.com\/index.php\/2026\/09\/23\/lords-mark-industries-gets-nod-for-final-clinical-trials-of-ai-breast-cancer-screening-device\/"},"modified":"2026-09-23T14:33:50","modified_gmt":"2026-09-23T09:03:50","slug":"lords-mark-industries-gets-nod-for-final-clinical-trials-of-ai-breast-cancer-screening-device","status":"publish","type":"post","link":"https:\/\/khabreindia.com\/index.php\/2026\/09\/23\/lords-mark-industries-gets-nod-for-final-clinical-trials-of-ai-breast-cancer-screening-device\/","title":{"rendered":"Lord&#8217;s Mark Industries Gets Nod for Final Clinical Trials of AI Breast Cancer Screening Device"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>New Delhi [India], September 23:<\/strong> Lord&#8217;s Mark Industries Limited has informed the BSE that its <strong>Technical Committee has approved the final clinical trial stage for its AI-powered, radiation-free wearable breast cancer screening device<\/strong>, with trials planned across the <strong>USA, Great Britain and Europe<\/strong>. The disclosure was made under <strong>Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015<\/strong>.<\/p>\n<p class=\"wp-block-paragraph\">The device, developed in collaboration with the <strong>Centre for Materials for Electronic Technology (C-MET)<\/strong>, uses <strong>thermal sensors and AI-based temperature mapping<\/strong> to identify abnormalities without radiation. According to the company, clinical trials in India have been completed, with <strong>Phase 2 trials targeting cell-level detection accuracy of 98% set to begin from January 2027 across India, the USA, Europe and Great Britain<\/strong>.<\/p>\n<p class=\"wp-block-paragraph\">Lord&#8217;s Mark holds <strong>exclusive commercialisation rights for the technology<\/strong>. The company said it is targeting completion of final trials and key regulatory milestones before <strong>March 2027<\/strong>, with commercial launch envisaged by <strong>April 2027<\/strong> \u2014 both subject to clinical outcomes and regulatory approvals. Regulatory evaluation in India is ongoing, with <strong>CDSCO approval in process<\/strong>; the company said it is also pursuing conformity requirements in Europe and <strong>FDA pathways in the US<\/strong>.<\/p>\n<p class=\"wp-block-paragraph\">Separately, the company noted it has made representations to relevant authorities seeking the technology&#8217;s inclusion in <strong>national breast cancer screening programmes<\/strong>, and to <strong>IRDAI for possible insurance coverage consideration<\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"<div class=\"tmnf_excerpt meta_deko\"><p>New Delhi India, September 23: Lord&#8217;s Mark Industries Limited has informed the BSE that its Technical Committee has approved the final clinical trial stage for its AI-powered, radiation-free wearable breast cancer screening device, with trials planned across the USA, Great Britain and Europe. The disclosure was made under Regulation 30 of the SEBI Listing Obligations &hellip;<\/p>\n<\/div>","protected":false},"author":1,"featured_media":36809,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[89],"tags":[3118,5640,5641,5642,5643,5644,5645,5647,5646],"class_list":["post-36810","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-ai-healthcare","tag-breast-cancer-screening","tag-c-met","tag-cdsco","tag-clinical-trials","tag-fda","tag-lords-mark","tag-medical-device","tag-thermal-imaging"],"_links":{"self":[{"href":"https:\/\/khabreindia.com\/index.php\/wp-json\/wp\/v2\/posts\/36810","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/khabreindia.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/khabreindia.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/khabreindia.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/khabreindia.com\/index.php\/wp-json\/wp\/v2\/comments?post=36810"}],"version-history":[{"count":0,"href":"https:\/\/khabreindia.com\/index.php\/wp-json\/wp\/v2\/posts\/36810\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/khabreindia.com\/index.php\/wp-json\/wp\/v2\/media\/36809"}],"wp:attachment":[{"href":"https:\/\/khabreindia.com\/index.php\/wp-json\/wp\/v2\/media?parent=36810"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/khabreindia.com\/index.php\/wp-json\/wp\/v2\/categories?post=36810"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/khabreindia.com\/index.php\/wp-json\/wp\/v2\/tags?post=36810"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}